Maki T, Lodge J P, Carretta M, Ohzato H, Borland K M, Sullivan S J, Staruk J, Muller T E, Solomon B A, Chick W L
Division of Organ Transplantation, New England Deaconess Hospital, Boston, Massachusetts.
Transplantation. 1993 Apr;55(4):713-7; discussion 717-8. doi: 10.1097/00007890-199304000-00005.
We report the successful application of a hybrid artificial pancreas device for the treatment of severe diabetes mellitus induced by total pancreatectomy in two dogs. Control of the blood sugar was achieved for more than 1 year in these two animals without any immunosuppressive therapy. Although exogenous insulin was required therapy. Although exogenous insulin was required during the latter part of the study period, removal of the devices resulted in a rapid increase in the fasting blood sugar levels and the exogenous insulin requirements (P < 0.001 versus weeks 1-52 in both dogs). Metabolic studies, postexplant in vitro studies, and histologic analyses confirmed islet cell survival and insulin production by the devices. This hybrid artificial pancreas has a clear clinical potential for islet cell transplantation without immunosuppression.
我们报告了一种混合人工胰腺装置在两只犬全胰切除术后所致严重糖尿病治疗中的成功应用。在未进行任何免疫抑制治疗的情况下,这两只动物的血糖得到了超过1年的控制。尽管在研究后期需要外源性胰岛素治疗,但移除该装置导致空腹血糖水平和外源性胰岛素需求量迅速增加(两只犬与第1 - 52周相比,P < 0.001)。代谢研究、装置移除后的体外研究以及组织学分析证实了胰岛细胞的存活以及该装置产生胰岛素。这种混合人工胰腺在无需免疫抑制的胰岛细胞移植方面具有明确的临床潜力。